30 April 2018
Seventure Partners invests in A-Mansia
A-Mansia Biotech S.A., a belgian microbiome company, announces a €13 million first close of its Series A financing, led by Seventure Partners.
All
12 April 2018
The LiMAx® liver capacity test is now commercially available in Germany, Austria and the UK
Humedics GmbH, a specialist in real-time measurement of individual liver function, today announced that the company has received Marketing Authorization for its diagnostic...
21 March 2018
Adisseo and Seventure Partners announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the...
8 March 2018
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...
31 January 2018
Seventure Partners announces that BPCE invests in its institutional funds, DIGITAL OPPORTUNITIES FUND
Paris, 31st January 2018 – Seventure Partners, a leading European player in innovation financing and affiliate of Natixis Investment Managers, announces today the second...
18 January 2018
Seventure Partners Life Sciences Investing Update – H2 2017
“2017 ended on a high note. Our Health For Life Capital™ investment vehicle has backed some truly remarkable disruptive technologies over the second half of the year and...
4 January 2018
Zipongo extends total financing to over $50M to launch FoodScripts™ and lower chronic disease costs
Zipongo plans to use the additional funding to expand its nutrition platform beyond wellness to use food as first-line therapy in treating chronic disease.
7 December 2017
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...
1 December 2017
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys
14 November 2017
Scipio bioscience announces its seed funding of €1.2m obtained from Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds
Scipio bioscience, a Paris-based biotechnology company devoted to providing a novel sample preparation solution for single-cell studies in the form of benchtop kits, announces...